Proteomics

Dataset Information

0

Resistance prediction in HGSOC with NACT using data-independent acquisition proteomics and an ovarian tissue-specific spectral library


ABSTRACT: We firstly built a high-quality ovarian tissue-specific spectral library containing 130,735 peptides and 10,696 proteins on Orbitrap instruments. Compared to a published pan-human spectral library (DPHL), this spectral library provides 10% more ovary-specific and 3% more ovary-enriched proteins. This library was then applied to analyze data-independent acquisition (DIA) data of tissue samples from an HGSOC cohort treated with NACT, leading to 10,070 proteins quantified, which is 9.73% more than that with DPHL. We then established a six-protein classifier by parallel reaction monitoring (PRM) to effectively predict the resistance of additional chemotherapy after IDS (Log-rank test, p = 0.002), which was further validated with 57 patients from an independent clinical center (p = 0.014). Together, we provided an ovary-specific spectral library for targeted proteome analysis, and proposed a six-protein classifier that could potentially predict chemoresistance in HGSOC patients after NACT-IDS treatment.

ORGANISM(S): Homo Sapiens

SUBMITTER: Tiannan Guo  

PROVIDER: PXD039160 | iProX | Mon Jan 02 00:00:00 GMT 2023

REPOSITORIES: iProX

altmetric image

Publications

Resistance prediction in high-grade serous ovarian carcinoma with neoadjuvant chemotherapy using data-independent acquisition proteomics and an ovary-specific spectral library.

Qian Liujia L   Zhu Jianqing J   Xue Zhangzhi Z   Gong Tingting T   Xiang Nan N   Yue Liang L   Cai Xue X   Gong Wangang W   Wang Junjian J   Sun Rui R   Jiang Wenhao W   Ge Weigang W   Wang He H   Zheng Zhiguo Z   Wu Qijun Q   Zhu Yi Y   Guo Tiannan T  

Molecular oncology 20230319 8


High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian cancer with 5-year survival rates below 40%. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is recommended for patients with advanced-stage HGSOC unsuitable for primary debulking surgery (PDS). However, about 40% of patients receiving this treatment exhibited chemoresistance of uncertain molecular mechanisms and predictability. Here, we built a high-quality ovary-specific spectral libr  ...[more]

Similar Datasets

2020-07-20 | PXD016047 | Pride
2019-08-15 | PXD011076 | Pride
2019-10-22 | PXD015026 | Pride
2023-05-17 | PXD037870 |
2025-05-15 | PXD061696 | Pride
2021-06-08 | PXD021937 | Pride
2024-07-19 | PXD046983 | Pride
2022-05-20 | PXD026395 | Pride
2021-08-23 | PXD025791 | Pride
2024-05-06 | PXD044981 | Pride